227 related articles for article (PubMed ID: 15868996)
1. [Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use].
van Strater AC; Bax JJ; van Hilten JJ; Jukema JW
Ned Tijdschr Geneeskd; 2005 Apr; 149(16):891-4. PubMed ID: 15868996
[TBL] [Abstract][Full Text] [Related]
2. Valvular heart disease associated with taking low-dose pergolide for restless legs syndrome.
Worthington A; Thomas L
Eur J Echocardiogr; 2008 Nov; 9(6):828-30. PubMed ID: 18579494
[TBL] [Abstract][Full Text] [Related]
3. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
Corvol JC; Anzouan-Kacou JB; Fauveau E; Bonnet AM; Lebrun-Vignes B; Girault C; Agid Y; Lechat P; Isnard R; Lacomblez L
Arch Neurol; 2007 Dec; 64(12):1721-6. PubMed ID: 18071034
[TBL] [Abstract][Full Text] [Related]
4. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
[TBL] [Abstract][Full Text] [Related]
5. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
Dewey RB; Reimold SC; O'Suilleabhain PE
Arch Neurol; 2007 Mar; 64(3):377-80. PubMed ID: 17353380
[TBL] [Abstract][Full Text] [Related]
6. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide.
Van Camp G; Flamez A; Cosyns B; Goldstein J; Perdaens C; Schoors D
Neurology; 2003 Sep; 61(6):859-61. PubMed ID: 14504342
[TBL] [Abstract][Full Text] [Related]
7. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
Kim JY; Chung EJ; Park SW; Lee WY
Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
[TBL] [Abstract][Full Text] [Related]
8. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
9. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation.
Baseman DG; O'Suilleabhain PE; Reimold SC; Laskar SR; Baseman JG; Dewey RB
Neurology; 2004 Jul; 63(2):301-4. PubMed ID: 15277624
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
[TBL] [Abstract][Full Text] [Related]
11. [Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease?].
Roth J; Ulmanová O; Růzicka E
Cas Lek Cesk; 2005; 144(2):123-6. PubMed ID: 15807300
[TBL] [Abstract][Full Text] [Related]
12. [Pergolide: a useful agonist for the treatment of Parkinson disease].
Bonnet AM; Houeto JL
Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
[TBL] [Abstract][Full Text] [Related]
13. Dopamine agonists and the risk of cardiac-valve regurgitation.
Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
[TBL] [Abstract][Full Text] [Related]
14. Pergolide in Parkinson's disease: time for a change?
Grosset KA; Grosset DG
Lancet; 2004 Jun; 363(9424):1907-8. PubMed ID: 15183636
[No Abstract] [Full Text] [Related]
15. Bromocriptine use and the risk of valvular heart disease.
Tan LC; Ng KK; Au WL; Lee RK; Chan YH; Tan NC
Mov Disord; 2009 Feb; 24(3):344-9. PubMed ID: 18989898
[TBL] [Abstract][Full Text] [Related]
16. Pergolide and Parkinson's disease: new preparation. No clear benefit.
Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
[TBL] [Abstract][Full Text] [Related]
17. The older Parkinson's disease drugs pergolide and cabergoline have been linked to heart problems. Are there any new Parkinson's drugs which are safer for patients with heart risks?
Heart Advis; 2009 Aug; 12(8):8. PubMed ID: 21188763
[No Abstract] [Full Text] [Related]
18. Valvular heart disease in patients taking pergolide.
Waller EA; Kaplan J; Heckman MG
Mayo Clin Proc; 2005 Aug; 80(8):1016-20. PubMed ID: 16092580
[TBL] [Abstract][Full Text] [Related]
19. [Multiple latency test in a patient with episodes of sleep induced by pergolide].
Jiménez-Jiménez FJ; Velasco I; de Toledo M; Sayed Y; Zurdo J; Ortí-Pareja M
Rev Neurol; 2002 Jun 16-30; 34(12):1140-1. PubMed ID: 12134281
[TBL] [Abstract][Full Text] [Related]
20. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide.
Jiménez-Jiménez FJ; López-Alvarez J; Sánchez-Chapado M; Montero E; Miquel J; Sierra A; Gutiérrez F
Clin Neuropharmacol; 1995 Jun; 18(3):277-9. PubMed ID: 8635187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
